Madrigal Pharmaceuticals

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a biopharmaceutical company based in West Conshohocken, Pennsylvania, focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). Its lead product, Rezdiffra (resmetirom), is the first FDA-approved treatment for MASH and is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist. Madrigal aims to address the high unmet medical need in serious liver diseases that can progress to cirrhosis and liver failure. The company collaborates with hepatology experts and is advancing pivotal clinical trials for its pipeline.